Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KYMR

+ Watchlist+ Portfolio

Kymera Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$121.52
52-Week Range
$63.69 – $142.92
Market Cap
$10.34B
P/E (TTM)
—
EPS (TTM)
-3.64
Dividend Yield
0.00%
Advanced Metrics
Price/Book
6.40
PEG Ratio
—
Return on Equity
-27.29%
Return on Assets
-17.64%
Gross Margin
0.00%
Operating Margin
-396.04%
Profit Margin
0.00%
Current Ratio
11.13
Debt/Equity
0.05
Total Debt
$76.60M
Free Cash Flow
$-164.68M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$9.45B

Market Snapshot

About

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing protein degradation therapies. The company's proprietary Pegasus platform enables the discovery of small molecule protein degraders that target disease-causing proteins for destruction. Kymera's pipeline includes investigational treatments for immunological diseases, oncology, and other therapeutic areas, utilizing targeted protein degradation as a novel mechanism of action.